PL2197428T3 - Ulepszona kompozycja farmaceutyczna zawierająca pirolidonowy środek przeciwdrgawkowy i sposób jej otrzymywania - Google Patents

Ulepszona kompozycja farmaceutyczna zawierająca pirolidonowy środek przeciwdrgawkowy i sposób jej otrzymywania

Info

Publication number
PL2197428T3
PL2197428T3 PL07819022T PL07819022T PL2197428T3 PL 2197428 T3 PL2197428 T3 PL 2197428T3 PL 07819022 T PL07819022 T PL 07819022T PL 07819022 T PL07819022 T PL 07819022T PL 2197428 T3 PL2197428 T3 PL 2197428T3
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical composition
composition containing
anticonvulsant agent
improved pharmaceutical
Prior art date
Application number
PL07819022T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthimios Koutris
Dimitrios Bikiaris
Vicky Samara
Ioanna Koutri
Eleni Stathaki
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Publication of PL2197428T3 publication Critical patent/PL2197428T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL07819022T 2007-10-16 2007-10-16 Ulepszona kompozycja farmaceutyczna zawierająca pirolidonowy środek przeciwdrgawkowy i sposób jej otrzymywania PL2197428T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07819022A EP2197428B1 (en) 2007-10-16 2007-10-16 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
PCT/EP2007/008952 WO2009049642A1 (en) 2007-10-16 2007-10-16 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof

Publications (1)

Publication Number Publication Date
PL2197428T3 true PL2197428T3 (pl) 2012-06-29

Family

ID=39494325

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07819022T PL2197428T3 (pl) 2007-10-16 2007-10-16 Ulepszona kompozycja farmaceutyczna zawierająca pirolidonowy środek przeciwdrgawkowy i sposób jej otrzymywania

Country Status (10)

Country Link
US (1) US8187635B2 (pl)
EP (1) EP2197428B1 (pl)
AT (1) ATE542525T1 (pl)
CA (1) CA2696977C (pl)
CY (1) CY1112702T1 (pl)
DK (1) DK2197428T3 (pl)
ES (1) ES2380010T3 (pl)
PL (1) PL2197428T3 (pl)
WO (1) WO2009049642A1 (pl)
ZA (1) ZA201003380B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666512B (zh) 2009-10-13 2014-11-26 奥斯特姆医疗公司 对疾病治疗有用的mek抑制剂
US9333175B2 (en) * 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
CA2906029C (en) 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
BR112022001968A2 (pt) * 2019-08-06 2022-05-10 Justin Kirkland Formulações que incluem di-hidrohonokiol
CN114917195B (zh) * 2022-06-13 2024-06-11 河北戴桥医药科技有限公司 一种吡拉西坦片剂及其制备方法
CN115869280A (zh) * 2022-11-15 2023-03-31 澳美制药(海南)有限公司 左乙拉西坦片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN1720025A (zh) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
WO2006070406A1 (en) 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
WO2006102750A1 (en) 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
EP1810676B1 (en) 2006-01-24 2008-11-12 Teva Pharmaceutical Industries Limited Levetiracetam formulations and methods for their manufacture

Also Published As

Publication number Publication date
CA2696977C (en) 2012-12-04
WO2009049642A1 (en) 2009-04-23
ZA201003380B (en) 2011-12-28
US8187635B2 (en) 2012-05-29
DK2197428T3 (da) 2012-04-02
CY1112702T1 (el) 2016-02-10
EP2197428B1 (en) 2012-01-25
EP2197428A1 (en) 2010-06-23
US20110033538A1 (en) 2011-02-10
ES2380010T3 (es) 2012-05-07
CA2696977A1 (en) 2009-04-23
ATE542525T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
ZA201003380B (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and methhod for the preparation thereof
MX2010000856A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihidropiridina y metodo para la preparacion de la misma.
TW200612892A (en) Novel compounds
MY142029A (en) Phenoxyacetic acid derivatives
MX2010003441A (es) Formulaciones galenicas de alisquireno y valsartan.
TW200745003A (en) Novel compounds
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2010049449A3 (en) Novel salts of sunitinib
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2008065485A3 (en) Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
MY146404A (en) Novel piperidine carboxylic acid amide derivatives
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
GR20070100405A (el) Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
MX2012001298A (es) Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano.
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
WO2010067989A3 (ko) 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
PL1906931T3 (pl) Ulepszona kompozycja farmaceutyczna zawierająca inhibitor ACE i sposób jej wytwarzania
ATE415151T1 (de) Formulierung zur verzögerten freisetzung von valproinsäure und deren derivate
MY150480A (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
WO2010067990A2 (ko) 신규한 6-인다졸릴아미노-3-니트로피리딘 유도체 화합물, 그의 제조방법 및 이를 포함하는 약제학적 조성물